Single-Patient Rooms for Safe Patient-Centered Hospitals

Abstract

1. Food and Drug Administration. Developing guidance on conducting scientifically sound pharmacoepidemiologic safety studies using large electronic healthcare data sets: public workshop: request for comments. Fed Regist. 2008;73 (79):21963-21964. 2. Food and Drug Administration. The Sentinel Initiative: national strategy for monitoring medical product safety. http://www.fda.gov/oc/initiatives/advance/reports /report0508.pdf. Accessed July 17, 2008. 3. Misbin RI. Medical office review of Avandia: application number: 021071: Center for Drug Evaluation and Research. http://oversight.house.gov/story.asp?ID= 1325. Accessed July 17, 2008. 4. Kahn SE, Haffner SM, Heise MA, et al; ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 2006; 355(23):2427-2443. 5. Gerstein HC, Yusuf S, Bosch J, et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet. 2006;368(9541):1096-1105. 6. Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycemia in Diabetes (RECORD) Study: interim findings on cardiovascular hospitalizations and deaths. N Engl J Med. 2007; 357(1):28-38. 7. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356(24):2457-2472. 8. Vandenbroucke J. Observational research, randomised trials, and two views of medical science. PLoS Med. 2008;5:e67; supplemental material. http://medicine .plosjournals.org/archive/1549-1676/5/3/supinfo/10.1371_journal.pmed.0050067 .sd001.pdf. 9. Joffe HV, Parks M, Meyer R, Jenkins J, Temple R. Rosiglitazone and the FDA. N Engl J Med. 2007;357(17):1775-1776. 10. Psaty BM, Ray W. FDA guidance on off-label promotion and the state of the literature from sponsors. JAMA. 2008;299(16):1949-1951. 11. Food and Drug Administration Amendments Act of 2007. HR 3580, enacted by the House and Senate, Pub L No. 110-85. http://frwebgate.access.gpo.gov /cgi-bin/getdoc.cgi?dbname=110_cong_billsd147(8):573-577. 13. Rossouw JE; Writing Group for the Women’s Health Initiative. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA. 2002; 288(3):321-333. 14. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: the Antihypertensive and LipidLowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA. 2002; 288(23):2998-3007. 15. Gerstein HC; Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008; 358(24):2545-2559.